{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:24:38Z","timestamp":1793834678254,"version":"4.6.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"25","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Adoptive T-cell therapy is a promising therapy for multiple myeloma (MM), but its efficacy hinges on understanding the relevant biologic and predictive markers of response. B-cell maturation antigen (BCMA) is a key target antigen in MM with active development of multiple anti-BCMA T-cell engagers (TCEs) and chimeric antigen receptor T-cell therapies. The regulation of surface BCMA expression by MM cells, which leads to shedding of soluble BCMA (sBCMA), has triggered debate about the significance of sBCMA as a predictive marker and its potential impact on treatment outcomes. To address this, we leveraged whole-genome sequencing and in\u00a0vitro assays to demonstrate that sBCMA may independently predict primary refractoriness to anti-BCMA therapies. In addition to sBCMA, tumor burden and surface BCMA antigen density collectively influenced the anti-BCMA TCE cytotoxic efficacy. Correlative analyses of 163 patients treated with the anti-BCMA TCE teclistamab validated and further underscored the association between elevated baseline sBCMA (&amp;gt;400 ng\/mL) and refractoriness. Importantly, increasing the TCE dose, using TCE against alternative targets (eg, GPRC5D), and gamma secretase inhibitors were able to overcome the high sBCMA levels. These findings highlight the importance of taking into account the baseline sBCMA levels, disease burden, and TCE dose intensity when administering anti-BCMA TCEs, thereby offering critical insights for optimizing therapeutic strategies to overcome specific high-risk features and primary anti-BCMA TCE refractoriness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026212","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:46:14Z","timestamp":1727286374000},"page":"2637-2651","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":92,"title":["Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma"],"prefix":"10.1182","volume":"144","author":[{"given":"Holly","family":"Lee","sequence":"first","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-6847","authenticated-orcid":false,"given":"Michael","family":"Durante","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"3Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"3Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Benaoudia","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Poorebrahim","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Barakat","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1390-6699","authenticated-orcid":false,"given":"David","family":"Jung","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4202-7127","authenticated-orcid":false,"given":"No\u00e9mie","family":"Leblay","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachisio","family":"Ziccheddu","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"2Sylvester Comprehensive Cancer Center, Myeloma Research Institute, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2024121916210796500_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024121916210796500_bib2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"31","key":"2024121916210796500_bib3","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A\u00a0phase I first-in-human study of ABBV-383, a B-cell maturation antigen\u00a0\u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024121916210796500_bib4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"S3","key":"2024121916210796500_bib5","doi-asserted-by":"crossref","first-page":"e1610068","DOI":"10.1097\/01.HS9.0000967700.16100.68","article-title":"S197: linker-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2024121916210796500_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2024121916210796500_bib7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121916210796500_bib8","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study [abstract]","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024121916210796500_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"2024121916210796500_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2024121916210796500_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"2024121916210796500_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"2024121916210796500_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024121916210796500_bib14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"7","key":"2024121916210796500_bib15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1101\/gr.080531.108","article-title":"The consensus coding sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes","volume":"19","author":"Pruitt","year":"2009","journal-title":"Genome Res"},{"issue":"1","key":"2024121916210796500_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.onc.1210637","article-title":"POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"issue":"13","key":"2024121916210796500_bib17","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","article-title":"CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma","volume":"4","author":"Ramkumar","year":"2020","journal-title":"Blood Adv"},{"key":"2024121916210796500_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","author":"Skerget","year":"2024;56:1878-1889","journal-title":"Nat Genet"},{"key":"2024121916210796500_bib19","unstructured":"Center for Drug Evaluation and Research\n          . NDA\/BLA Multi-disciplinary Review and Evaluation Application number 761291Orig1s000. Accessed 30 March 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761291Orig1s000MultidisciplineR.pdf."},{"key":"2024121916210796500_bib20","unstructured":"Center for Drug Evaluation and Research\n          . NDA\/BLA Multi-disciplinary Review and Evaluation Application number 761345Orig1s000. Accessed 30 March 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761345Orig1s000MultidisciplineR.pdf."},{"issue":"3","key":"2024121916210796500_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"19","key":"2024121916210796500_bib22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple\u00a0myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2024121916210796500_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024121916210796500_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10297","key":"2024121916210796500_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma\u00a0(CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2024121916210796500_bib26","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2024121916210796500_bib27","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"2024121916210796500_bib28","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2024121916210796500_bib29","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2024121916210796500_bib30","first-page":"1995","article-title":"Elranatamab exposure-efficacy analysis in patients with relapsed or refractory multiple myeloma: insights from pooled MagnetisMM studies [abstract]","volume":"142","author":"Kei","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916210796500_bib31","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2023-190341","article-title":"Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) MagnetisMM studies [abstract]","volume":"142","author":"Elmeliegy","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024121916210796500_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in MajesTEC-1","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2024121916210796500_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"issue":"4","key":"2024121916210796500_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"S3","key":"2024121916210796500_bib35","doi-asserted-by":"crossref","first-page":"e162590e","DOI":"10.1097\/01.HS9.0000970364.16259.0e","article-title":"P865: teclistamab in combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1B multicohort MAJESTEC-2 study","volume":"7","author":"Tan","year":"2023","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2024121916210796500_bib36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1B, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916210796500_bib37","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 MagnetisMM-5 study safety lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916210796500_bib38","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1182\/blood-2022-166854","article-title":"MagnetisMM-4: an open label, phase 1B\/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121916210796500_bib39","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T cell engager (TCE), and CELMoD agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024121916210796500_bib40","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"issue":"10","key":"2024121916210796500_bib41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","article-title":"Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma","volume":"30","author":"Oliver-Caldes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2024121916210796500_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.HS9.0000846344.56300.e1","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma patients treated with idecabtagene vicleucel (BB2121)","volume":"6","author":"Rytlewski","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl","key":"2024121916210796500_bib43","doi-asserted-by":"crossref","first-page":"e7421475","DOI":"10.1097\/01.HS9.0000970108.74214.75","article-title":"Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class\u2013exposed relapsed and refractory multiple myeloma","volume":"7","author":"Piasecki","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 16","key":"2024121916210796500_bib44","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"S3","key":"2024121916210796500_bib45","doi-asserted-by":"crossref","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: teclistamab (TEC)\u00a0+ nirogacestat (NIRO) in\u00a0relapsed\/refractory multiple myeloma\u00a0(RRMM): the phase 1B MAJESTEC-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"2024121916210796500_bib46","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"2024121916210796500_bib47","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1538-7445.AM2020-4557","article-title":"Abstract 4557: BCMA-CD3 bispecific antibody PF-06863135: preclinical rationale for therapeutic combinations","volume":"80","author":"Karwacz","year":"2020","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"2024121916210796500_bib48","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator\u2019s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2637\/2347095\/blood_bld-2024-026212-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/25\/2637\/2347095\/blood_bld-2024-026212-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:31:40Z","timestamp":1734607900000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/25\/2637\/517991\/Impact-of-soluble-BCMA-and-non-T-cell-factors-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":48,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,12,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026212","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}